Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating adding BAY 1895344 to standard chemotherapy for advanced solid tumors, focusing on small cell lung cancer, poorly differentiated neuroe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma
• Pancreatic Adenocarcinoma
• Small Cell Lung Cancer

Drugs mentioned

• BAY 1895344 (BAY 1895344)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm | Phase 1 | Status: ACTIVE_NOT_RECRUITING